Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27948910 | 0.89 | HMGB1 (0.56) | PDE3BPDE3ASMN1; SMN2TSHRGABRA1 | |
| SCHEMBL9749183 | 0.81 | BCL2 (0.54) | KDM4E | |
| SCHEMBL9748865 | 0.81 | PTPN1 (0.64) | TSHR | |
| SCHEMBL10792105 | 0.79 | TSHR (0.57) | PDE3BPDE3ASMN1; SMN2TSHR | |
| SCHEMBL9749162 | 0.79 | PTPN1 (0.53) | TSHR | |
| SCHEMBL9750299 | 0.79 | PTPN1 (0.53) | TSHR | |
| SCHEMBL3642333 | 0.78 | TSHR (0.65) | PDE3BPDE3ASMN1; SMN2TSHRGABRA1 | |
| SCHEMBL19737311 | 0.77 | ALDH1A1 (0.59) | SMN1; SMN2TSHRKDM4E | |
| SCHEMBL29246749 | 0.77 | KDM4E (0.57) | TSHRKDM4E | |
| Bicarbonate SCHEMBL27544354 | 0.77 | TSHR (0.62) | PDE3BPDE3ASMN1; SMN2TSHRGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0201071-B1 | 2-SUBSTITUTED-1-NAPHTHOLS AS 5-LIPOXYGENASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-03-04 | — | — | EP | disclosed |
| US-5026759-A | Antiinflammatory agents respiratory system disorders | DU PONT MERCK PHARMACEUTICAL (US) | 1991-06-25 | — | — | US | disclosed |
| US-4985442-A | ANTIINFLAMMATORY, LUNG DISEASES, PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4985435-A | TREATMENT OF INFLAMMATION, OBSTRUCTIVE LUNG DISEASES AND PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4906636-A | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
| US-4833164-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-23 | — | — | US | disclosed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | disclosed |